Search Results - "Connors, Jean M. M"

Thrombophilia Testing and Venous Thrombosis by Connors, Jean M

“…Most patients with venous thromboembolism do not require thrombophilia testing, since the results will not affect management. Testing may be considered in…”
Get full text

COVID-19 and its implications for thrombosis and anticoagulation by Connors, Jean M., Levy, Jerrold H.

“…Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings…”
Get full text

Thromboinflammation and the hypercoagulability of COVID‐19 by Connors, Jean M., Levy, Jerrold H.

Get full text

Testing and monitoring direct oral anticoagulants by Connors, Jean M.

“…Direct oral anticoagulants (DOACs) have significantly improved the care of patients requiring anticoagulation. With similar or better efficacy and safety…”
Get full text

Heparin Resistance — Clinical Perspectives and Management Strategies by Levy, Jerrold H, Connors, Jean M

“…Heparin resistance is suspected when more heparin than usual is needed to achieve a therapeutic range of activated partial-thromboplastin time. Management may…”
Get full text

New Oral Anticoagulants and the Cancer Patient by Short, Nicholas J., Connors, Jean M.

“…Learning Objectives Cite the current indications, basic clinical pharmacology, and rationale for development of the new oral anticoagulants. Explain the…”
Get full text

Update on Guidelines for the Management of Cancer‐Associated Thrombosis by Streiff, Michael B., Abutalib, Syed Ali, Farge, Dominique, Murphy, Martina, Connors, Jean M., Piazza, Gregory

“…Cancer‐associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been…”
Get full text

Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy by Barra, Megan E., PharmD, Fanikos, John, RPh, MBA, Connors, Jean M., MD, Sylvester, Katelyn W., PharmD, Piazza, Gregory, MD, MS, Goldhaber, Samuel Z., MD

“…Abstract Background Compared with vitamin K antagonists, direct acting oral anticoagulants (DOACs) have fixed dosing, limited drug interactions, and do not…”
Get full text

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy by Al-Samkari, Hanny, Connors, Jean M.

“…The association between malignancy and thrombosis has been recognized for over a century and a half. Patients with cancer have an elevated risk of both initial…”
Get full text

What Role Does Microthrombosis Play in Long COVID? by Iba, Toshiaki, Connors, Jean M, Levy, Jerrold H

“…Soon after the outbreak of coronavirus disease 2019 (COVID-19), unexplained sustained fatigue, cognitive disturbance, and muscle ache/weakness were reported in…”
Get more information

Guidance for the treatment of deep vein thrombosis and pulmonary embolism by Streiff, Michael B., Agnelli, Giancarlo, Connors, Jean M., Crowther, Mark, Eichinger, Sabine, Lopes, Renato, McBane, Robert D., Moll, Stephan, Ansell, Jack

“…This guidance document focuses on the diagnosis and treatment of venous thromboembolism (VTE). Efficient, cost effective diagnosis of VTE is facilitated by…”
Get full text

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies by Al-Samkari, Hanny, Parnes, Aric D, Goodarzi, Katayoon, Weitzman, James I, Connors, Jean M, Kuter, David J

“…Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy delays, dose reductions, and discontinuation. There is…”
Get full text

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials by Frere, Corinne, Farge, Dominique, Schrag, Deborah, Prata, Pedro H, Connors, Jean M

“…International clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins…”
Get full text

Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH by Spyropoulos, Alex C., Connors, Jean M., Douketis, James D., Goldin, Mark, Hunt, Beverley J., Kotila, Taiwo R., Lopes, Renato D., Schulman, Sam, the International Society on Thrombosis and Haemostasis

“…Despite the emergence of high quality randomized trial data with the use of antithrombotic agents to reduce the risk of thromboembolism, end‐organ failure, and…”
Get full text

Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial by Becattini, Cecilia, Bauersachs, Rupert, Maraziti, Giorgio, Bertoletti, Laurent, Cohen, Alexander, Connors, Jean M., Manfellotto, Dario, Sanchez, Antonio, Brenner, Benjamin, Agnelli, Giancarlo

“…The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous…”
Get full text

COVID‐19: Thrombosis, thromboinflammation, and anticoagulation considerations by Levy, Jerrold H., Iba, Toshiaki, Olson, Lyra B., Corey, Kristen M., Ghadimi, Kamrouz, Connors, Jean M.

“…Vascular endothelial injury is a hallmark of acute infection at both the microvascular and macrovascular levels. The hallmark of SARS‐CoV‐2 infection is the…”
Get full text

Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials by Talasaz, Azita H., Sadeghipour, Parham, Aghakouchakzadeh, Maryam, Kakavand, Hessam, Ariannejad, Hamid, Connors, Jean M., Hunt, Beverley J., Berger, Jeffrey S., Van Tassell, Benjamin W., Middeldorp, Saskia, Piazza, Gregory, Weitz, Jeffrey I., Cushman, Mary, Lip, Gregory Y. H., Goldhaber, Samuel Z., Bikdeli, Behnood

“…Background Coronavirus disease 2019 (COVID‐19) is associated with macro‐ and micro‐thromboses, which are triggered by endothelial cell activation,…”
Get full text

Editorial: Hemostasis in ECMO and VAD, volume II by Teruya, Jun, Connors, Jean M, Zieger, Barbara

Get full text

Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation by El-Chemaly, Souheil, O'Brien, Kevin J, Nathan, Steven D, Weinhouse, Gerald L, Goldberg, Hilary J, Connors, Jean M, Cui, Ye, Astor, Todd L, Camp, Jr, Philip C, Rosas, Ivan O, Lemma, Merte, Speransky, Vladislav, Merideth, Melissa A, Gahl, William A, Gochuico, Bernadette R

“…Pulmonary fibrosis is a progressive, fatal manifestation of Hermansky-Pudlak syndrome (HPS). Some patients with advanced HPS pulmonary fibrosis undergo lung…”
Get full text

Venous thromboembolism is associated with graft- versus -host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation by Kekre, Natasha, Kim, Haesook T, Ho, Vincent T, Cutler, Corey, Armand, Philippe, Nikiforow, Sarah, Alyea, Edwin P, Soiffer, Robert J, Antin, Joseph H, Connors, Jean M, Koreth, John

“…Although venous thromboembolism rates and risk factors are well described in patients with cancer, there are limited data on the incidence, risk factors and…”
Get full text